2616 — CStone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$7.77bn
- HK$6.36bn
- CNY269.58m
CStone Pharmaceuticals drops most in near 5 months on discounted share sale
Brief: Cstone Pharmaceuticals To Place Aggregate Of 84.8 Mln Shares For Hk$4.633 Per Share
HK-listed CStone jumps most in over 1-1/2 years on robust results forecast
Brief: CStone Pharmaceuticals Sees Total Revenue For Year To Be Not Less Than RMB475.0 Mln
Brief: CStone Pharmaceuticals Says NDA For Gavreto (Pralsetinib) Approved In Taiwan
Brief: CStone Pharmaceuticals Announces Acceptance Of Marketing Authorization Application By UK MHRA
Brief: Cstone Pharmaceuticals Says CEO Purchased Total Of 570,000 Shares In Open Market Since Nov
Brief: CStone Pharmaceuticals Updates On Registrational Study Of Sugemalimab
Brief: Cstone Pharmaceuticals Says CEO Purchased Total Of 1.6 Mln Shares In Open Market Since Sept 2022
Brief: Cstone Pharmaceuticals Says Chief Executive Officer Purchased 1 Million Shares
Brief: GIC's Long Position In CStone Pharma Falls To 5.99% - HKEx Filing
Brief: Cstone Pharmaceuticals Says China's NMPA Accepted & Granted Priority Review To Supplemental New Drug Application For Sugemalimab
Brief: Cstone Pharmaceuticals - Frank Ningjun Jiang Decided To Retire As CEO
Brief: Cstone Pharmaceuticals Records HY Loss For Period Rmb361.6 Mln
Media: Wuxi-Backed Chinese Biotech Cstone Considers Sale - Bloomberg News
Brief: Cstone And Pfizer Announce NMPA Approval Of Sugemalimab In Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Brief: Cstone Pharmaceuticals Says FY Loss Rmb1,920.1 Mln Versus Loss Rmb1,221.0 Mln
Jefferies sees high likelihood of U.S. approval for four China-developed drugs
Brief: CStone Pharmaceuticals Announces Publication Of Results From Phase III Agile Trial Of Tibsovo